HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

HABP and VABP are extremely challenging infections to manage for various reasons. Here’s my take on how new recommendations and tools can help lead to early effective therapy.

Keith S. Kaye, MD, MPH Released: January 24, 2022

Guidelines for hospital-acquired and ventilator-associated bacterial pneumonia are great, but you have to bring it back to the individual.

Lilian Abbo, MD, FIDSA Released: February 11, 2022

The problem with antibiograms is that they capture essentially the first specimen from a patient, and flora change with time and treatment.

Lilian Abbo, MD, FIDSA Released: March 8, 2022

Working closely with frontline ICU pharmacists and physicians is vital to obtaining microbiological histories, recent antimicrobial exposures, and drug allergies to optimize therapy on an individual level.

Jason M. Pogue, PharmD Released: April 14, 2022

Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Lilian Abbo, MD, FIDSA Keith S. Kaye, MD, MPH Jason M. Pogue, PharmD Released: February 18, 2022

Listen to expert insights on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Keith S. Kaye, MD, MPH
Program Director Lilian Abbo, MD, FIDSA Jason M. Pogue, PharmD Released: March 15, 2022

Hear expert insights on key concepts in HABP/VABP and Gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Keith S. Kaye, MD, MPH
Program Director Lilian Abbo, MD, FIDSA Jason M. Pogue, PharmD Physicians: maximum of 1.75 AMA PRA Category 1 Credits™ Pharmacists: 1.75 contact hours (0.175 CEUs) Released: March 23, 2022 Expired: March 22, 2023

Introduction

Epidemiology and Risk Factors

Antimicrobial Resistance in HABP/VABP

New Antimicrobial Agents for MDR Gram-Negative Infections: Latest Data

Discussion and Conclusions